Zelira Therapeutics Limited (ZLDAF) Stock Price & Analysis
Zelira Therapeutics Limited (ZLDAF) — price $0.2045 (0.00%), as of the Nov 19, 2026 trading session; market cap $2.69M.
Educational signal · not a buy or sell recommendation · How to read this
Zelira Therapeutics Limited · ZLDAF
Zelira Therapeutics Limited (ZLDAF) is an Australian biopharmaceutical company focused on cannabinoid-derived therapeutic agents for various medical conditions. The company is actively developing its product pipeline, including cannabinoid-based medicines for chronic insomnia and other health issues.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.2045 | |
| Change on the day | 0.00% | |
| 52-week range | $0.0089 – $0.4165 | |
| Market capitalisation | $2.69M | |
| Shares traded on the day | 571 |
Price & events
Other perspectives
Council score for Zelira Therapeutics (ZLDAF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Zelira Therapeutics (ZLDAF), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Zelira Therapeutics Limited (ZLDAF) is the company analyzed here. It employs 8 people and is led by Oludare Odumosu. In Q4 FY2025 it reported revenue of A$0.658 and net income of -A$1M. The market values it at $2.69M.
What do the latest results show for Zelira Therapeutics (ZLDAF)?
Short answer · as of
The most recent reported quarter, Q4 FY2025, carried revenue of A$0.658.
Quarterly income statement — 3 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 FY2025 | A$0.658 | -A$1M | -A$0.10 (diluted) |
| Q2 FY2025 | A$655 | -A$2M | -A$0.21 (diluted) |
| Q4 FY2024 | A$40,229 | -A$2M | -A$0.21 (diluted) |
What are the financial strengths and risks for Zelira Therapeutics (ZLDAF)?
Short answer · as of
The distress and quality screens read Piotroski F 1. Trailing ratios: ROE 80.8% · current ratio 0.11 · earnings yield -63.2% · free-cash-flow yield -74.6%.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held ZLDAF in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported ZLDAF in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Zelira Therapeutics Stock: Key Questions Answered
These answers are editorial: 1 of these 8 answers is drawn from the ZLDAF research dossier (written Jun 14, 2026 by gpt-4o-mini); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is ZLDAF a good stock to buy?
Stock Expert AI does not rate ZLDAF buy, sell or hold. Zelira Therapeutics Limited has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the ZLDAF stock price today?
The last price recorded for Zelira Therapeutics Limited (ZLDAF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for ZLDAF?
Zelira Therapeutics Limited faces several risks, including regulatory challenges that could impact the cannabis industry and its operations. The company also contends with intense competition from established pharmaceutical firms and market volatility due to its OTC trading status, which may affect liquidity and stock price stability.
What are the key factors to evaluate for ZLDAF?
Evaluate ZLDAF on fundamentals, analyst consensus, and risk factors. No dividend yield as the company is reinvesting earnings into product development and clinical trials. Not financial advice.
How frequently does ZLDAF data refresh on this page?
ZLDAF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven ZLDAF's recent stock price performance?
Zelira Therapeutics Limited (ZLDAF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative focus on cannabinoid-derived therapeutics. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ZLDAF overvalued or undervalued right now?
Zelira Therapeutics Limited (ZLDAF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research ZLDAF before investing?
Before investing in Zelira Therapeutics Limited (ZLDAF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 13 figures on this page — 8 from Financial Modeling Prep (FMP) and 5 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com